Target identification: HIF2alpha central player in osteoarthritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Biological aspects of early osteoarthritis.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2012
   Pooled it
2. Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS.Arthritis research & therapy · 2015
   Article
3. Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice.Gene therapy · 2015
   Article

Corrections and comments

• Comment on
  Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction.2010
• Comment on
  Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.